3 Stocks Estimated To Be Undervalued In September 2026
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by an impressive 18%, with earnings forecasted to grow by 17% annually. In this environment of growth and stability, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on discrepancies between a company's intrinsic value and its current market price.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Vertex (VERX) | $13.78 | $27.50 | 49.9% |
| Symbotic (SYM) | $41.60 | $80.82 | 48.5% |
| OceanFirst Financial (OCFC) | $19.28 | $38.44 | 49.8% |
| Mobileye Global (MBLY) | $8.32 | $16.48 | 49.5% |
| Luckin Coffee (LKNC.Y) | $33.96 | $65.88 | 48.4% |
| Inter & Co (INTR) | $5.80 | $11.58 | 49.9% |
| Flex (FLEX) | $107.89 | $202.75 | 46.8% |
| Coherent (COHR) | $264.41 | $528.42 | 50% |
| Boeing (BA) | $210.51 | $394.61 | 46.7% |
| Alerus Financial (ALRS) | $33.37 | $63.27 | 47.3% |
Let's take a closer look at a couple of our picks from the screened companies.
Solstice Advanced Materials (SOLS)
Overview: Solstice Advanced Materials, Inc. is a specialty chemicals and advanced materials company with operations in the United States and internationally, and it has a market cap of $9.69 billion.
Operations: The company generates revenue through its Electronic & Specialty Materials segment, which accounts for $1.14 billion, and its Refrigerants & Applied Solutions segment, contributing $2.96 billion.
Estimated Discount To Fair Value: 38.7%
Solstice Advanced Materials is trading at $61.37, below its estimated future cash flow value of $100.05, suggesting it may be undervalued based on cash flows. Despite a high debt level, the company anticipates significant earnings growth of 22% annually over the next three years, outpacing the US market's 17.1%. Recent guidance revisions indicate rising net sales expectations for 2026 between $4.13 billion and $4.19 billion, reflecting strong financial performance despite lower profit margins compared to last year.
- Insights from our recent growth report point to a promising forecast for Solstice Advanced Materials' business outlook.
- Take a closer look at Solstice Advanced Materials' balance sheet health here in our report.
AbbVie (ABBV)
Overview: AbbVie Inc. is a research-based biopharmaceutical company involved in the research, development, manufacturing, commercialization, and sale of medicines and therapies globally, with a market cap of $462.49 billion.
Operations: The company's primary revenue segment, generating $64.39 billion, is Innovative Medicines and Therapies.
Estimated Discount To Fair Value: 42.5%
AbbVie is trading at US$260.21, significantly below its estimated future cash flow value of US$452.31, indicating potential undervaluation based on cash flows. Despite high debt levels, the company forecasts robust earnings growth of 23.4% annually over the next three years, surpassing the US market's average growth rate of 17.1%. Recent positive trial results for etentamig in multiple myeloma and increased revenue guidance underscore AbbVie's strong financial position and promising pipeline developments.
- Our comprehensive growth report raises the possibility that AbbVie is poised for substantial financial growth.
- Unlock comprehensive insights into our analysis of AbbVie stock in this financial health report.
Oracle (ORCL)
Overview: Oracle Corporation provides products and services designed to build, run, and support enterprise information technology frameworks globally, with a market cap of approximately $419.83 billion.
Operations: Oracle's revenue is primarily derived from three segments: Cloud and software at $58.53 billion, Services at $5.74 billion, and Hardware at $3.08 billion.
Estimated Discount To Fair Value: 29.8%
Oracle is trading at US$154.04, below its estimated future cash flow value of US$219.28, suggesting it may be undervalued based on cash flows. The company anticipates revenue growth of 24.7% annually, outpacing the broader U.S. market's growth rate. Despite a high debt level, Oracle's strategic partnerships and AI-driven innovations in cloud services bolster its financial outlook and operational capabilities across multiple sectors including healthcare and manufacturing.
- Our growth report here indicates Oracle may be poised for an improving outlook.
- Click here to discover the nuances of Oracle with our detailed financial health report.
Where To Now?
- Investigate our full lineup of 150 Undervalued US Stocks Based On Cash Flows right here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com